Tohoku Chemical Co Ltd

Tohoku Chemical maintains a conservative capital structure with a debt-to-equity ratio of 0.1, indicating minimal leverage and strong equity backing. The company's liquidity position is robust, with a current ratio of 1.35 and cash and equivalents of ¥924.6 million, which supports operational flexibility and short-term obligations. The price-to-book ratio of 0.52 suggests the company is trading at a discount to its book value, potentially reflecting market skepticism about asset quality or growth prospects. Profitability metrics show a return on equity (ROE) of 5.41% and a return on assets (ROA) of 2.33%, both below the typical thresholds for high-performing chemical distributors. These figures indicate that Tohoku Chemical is generating modest returns relative to its equity and asset base. Gross profit of ¥3.29 billion and operating income of ¥517.2 million highlight a narrow margin structure, consistent with the competitive nature of the commodity chemicals industry. The company's revenue is distributed across four segments: Industrial Chemicals, Clinical Test Reagents, Food, and Others. The Industrial Chemical segment is the largest contributor, with a focus on industrial chemicals and related equipment. The Clinical Test Reagent segment provides reagents and equipment for medical diagnostics, while the Food segment offers food products and additives. The Others segment includes agrochemicals and related equipment. Revenue concentration data is not explicitly provided, but the multi-segment structure suggests diversification. Looking ahead, Tohoku Chemical's growth trajectory appears modest. The company's current FY outlook does not indicate significant revenue acceleration, and the next FY direction is expected to remain stable. Historical revenue growth has been limited, with the most recent reported revenue at ¥34.44 billion. The company's capital expenditure of -¥20.0 million suggests a focus on cost control rather than expansion. Risk factors for Tohoku Chemical include exposure to commodity price volatility and regulatory changes in the chemicals and medical diagnostics sectors. The company's liquidity risk is low, supported by strong cash reserves and a low debt burden. However, the low ROE and ROA suggest that the company may struggle to generate strong returns in a highly competitive market. Dilution risk is also low, with no immediate filing-based flags detected, and the company's share count has remained stable. Recent events and filings do not indicate any material changes in the company's operations or financial position. The latest actual EPS of ¥475.93 and revenue of ¥34.44 billion align with the company's historical performance, suggesting a stable but unremarkable trajectory.